|1.||Stewart, Clinton F: 27 articles (09/2015 - 03/2002)|
|2.||Abramson, David H: 14 articles (10/2015 - 08/2007)|
|3.||Pommier, Yves: 12 articles (12/2014 - 08/2002)|
|4.||Coleman, Robert L: 11 articles (12/2015 - 01/2002)|
|5.||Schaiquevich, Paula: 11 articles (10/2015 - 11/2007)|
|6.||Sugimoto, Yoshikazu: 11 articles (07/2011 - 03/2002)|
|7.||Herzog, Thomas J: 11 articles (03/2011 - 01/2002)|
|8.||Monk, Bradley J: 9 articles (03/2015 - 07/2005)|
|9.||Doroshow, James H: 9 articles (12/2014 - 02/2010)|
|10.||Chantada, Guillermo L: 9 articles (09/2014 - 03/2004)|
11/01/2007 - "The broad clinical effectiveness and manageable toxicity of topotecan in other human malignancies as well as promising recent study results suggest that it is highly effective in treating cervical tumors. "
12/01/2004 - "Topotecan given as a weekly bolus is a highly active and well-tolerated treatment regimen for relapsed ovarian and primary peritoneal cancer and thus deserves further evaluation."
10/01/2004 - "Concomitant with HIF-1alpha inhibition, topotecan caused a significant tumor growth inhibition associated with a marked decrease of angiogenesis and expression of HIF-1 target genes in tumor tissue. "
08/01/2003 - "The administration of CpG 2006 with topotecan significantly improved survival in mice with large tumors. "
10/01/2005 - "The anti-cancer effect studies in murine heptocarcinoma H(22) tumour-bearing mice showed that H-PEG improved the therapeutic efficiency of topotecan and decreased the toxicity of topotecan to a certain extent compared with H-Lip. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
03/01/2009 - "The peer-reviewed literature reports that topotecan is an effective, well tolerated treatment option for relapsed ovarian cancer."
03/01/2005 - "Intraperitoneal administration of topotecan as consolidation therapy in patients with ovarian cancer has shown promising results. "
03/01/1996 - "Trial of topotecan as first-line treatment for ovarian cancer announced."
08/01/2005 - "Weekly topotecan may be an appropriate treatment option for patients with recurrent ovarian cancer, especially heavily pretreated patients who might require dosing schedules with improved tolerability."
12/01/2004 - "To retrospectively investigate the safety and efficacy of weekly topotecan in heavily pretreated patients with ovarian cancer. "
|3.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/2010 - "Intravenous topotecan was at least as effective as CAV in the treatment of patients with recurrent small-cell lung cancer and resulted in improved quality-of-life with respect to several symptoms. "
06/01/2006 - "Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer."
12/01/2004 - "In patients with recurrent small-cell lung cancer, who frequently present with a compromised PS, the use of topotecan as a single agent led to an improvement in PS in approximately one third of these patients without excessive toxicities. "
01/01/2004 - "Topotecan in the first-line treatment of small cell lung cancer."
05/01/2002 - "[A case of recurrent small cell lung cancer with symptoms improved by nogitecan hydrochloride]."
07/01/2000 - "Further, in a human breast carcinoma model (MDA 435/LCC6), liposomal topotecan provided greatly improved increase in life span relative to the free drug. "
03/01/2003 - "Although topotecan's antitumor activity cannot yet be quantified, disease-free interval and survival outcomes compare favorably with other therapies in uterine serous carcinoma. "
10/15/2002 - "Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma."
03/01/2013 - "Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience."
03/01/2011 - "This Phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma. "
06/20/2005 - "Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach."
11/20/2011 - "Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study."
01/01/2008 - "The study aims to use mathematical modeling and simulation to assess the relative contribution of topotecan systemic exposure and scheduling in the activity and myelosuppression of topotecan in pediatric patients with neuroblastoma. "
04/01/2005 - "Secondly, the other aim of this study was to determine whether it is feasible to combine this treatment with the topotecan in children with metastatic neuroblastoma. "
11/01/2015 - "Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan."
|5.||Type I DNA Topoisomerases (Topoisomerase I)
|7.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Stem Cell Transplantation